基于胸部CT评估中度COVID-19肺炎后1年结局
前瞻性研究连续纳入84例因中度COVID-19肺炎住院的患者,在首次诊断后3、6、12个月行高分辨率胸部CT随访。基线磨玻璃影1年时从100%降至2%,实变6个月时从71%降至0%,纤维化样异常3个月为50%、1年为5%,1年时93%(78/84)患者肺部异常完全吸收,无纤维化证据。
要点
- 中度COVID-19肺炎住院患者1年时93%(78/84)胸部CT肺部异常完全吸收。
- 磨玻璃影基线患病率100%,1年降至2%;实变基线71%,6个月降至0%。
- 纤维化样异常3个月50%、6个月42%、1年5%,以胸膜肺实质带最常见。
核心结论
- 中度COVID-19肺炎住院患者残留肺部异常不常见,1年胸部CT无纤维化证据。
研究设计与样本
- 前瞻性研究,连续纳入2020年3月至2021年7月一家三级医疗中心放射科随访的既往COVID-19肺炎住院患者84例(男56例,平均年龄61岁±11[SD]);排除急性呼吸窘迫综合征、需插管和/或机械通气、肺栓塞及任何间质性肺病;在首次诊断后3、6、12个月行高分辨率容积非增强胸部CT并与基线CT比较。
关键影像表现/征象
- 基线主要异常为磨玻璃影和实变,中位严重度评分9分(IQR 7-12.7;最高可能评分20分),提示中度肺部受累。
- 磨玻璃影患病率从基线100%降至1年时2%;实变从基线71%降至6个月时0%。
- 纤维化样异常(胸膜肺实质带、线状肺不张、支气管和/或细支气管扩张)3个月见于50%患者、6个月42%、1年5%,其中胸膜肺实质带最常见。
- 纤维化改变(网格影和牵拉性支气管和/或细支气管扩张)3-6个月见于2%患者,1年保持稳定,无蜂窝状改变证据。
诊断标准与关键数值
- 分析的影像特征包括磨玻璃影、实变、胸膜肺实质带、线状肺不张、支气管和/或细支气管扩张、网格影、牵拉性支气管和/或细支气管扩张及蜂窝状改变。
- 基线中位严重度评分9分(IQR 7-12.7;最高可能评分20分),提示中度肺部受累。
- 1年时78/84(93%)患者COVID-19肺炎所致肺部异常完全吸收。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: COVID-19 pneumonia may lead to pulmonary fibrosis in the long term. Chest CT is useful to evaluate changes in the lung parenchyma over time.
PURPOSE: To illustrate the temporal change of lung abnormalities on chest CT scans associated with COVID-19 pneumonia over 1 year.
MATERIALS AND METHODS: In this prospective study, patients previously hospitalized due to COVID-19 pneumonia who visited the radiology department of a tertiary care center for imaging follow-up were consecutively enrolled between March 2020 and July 2021. Exclusion criteria were acute respiratory distress syndrome, requirement of intubation and/or mechanical ventilation, pulmonary embolism, and any interstitial lung disease. High-resolution volumetric noncontrast chest CT scans were acquired at 3, 6, and 12 months from the first diagnosis and were compared with baseline CT scans. The imaging features analyzed were ground-glass opacity (GGO), consolidation, pleuroparenchymal band, linear atelectasis, bronchiectasis and/or bronchiolectasis, reticulation, traction bronchiectasis and/or bronchiolectasis, and honeycombing. The prevalence distribution of lung abnormalities was recorded at all time points.
RESULTS: Eighty-four participants (56 men; mean age, 61 years ± 11 [SD]) were studied. GGOs and consolidations represented the main baseline lung abnormalities, accounting for a median severity score of 9 (IQR, 7-12.7; maximum possible score, 20), which indicates moderate lung involvement. The baseline prevalence of GGOs decreased from 100% to 2% of participants at 1 year, and that of consolidations decreased from 71% to 0% at 6 months. Fibrotic-like abnormalities (pleuroparenchymal bands, linear atelectasis, bronchiectasis and/or bronchiolectasis) were detected at 3 months (50% of participants), 6 months (42% of participants), and 1 year (5% of participants). Among these, pleuroparenchymal bands were the most represented finding. Fibrotic changes (reticulation and traction bronchiectasis and/or bronchiolectasis) were detected at 3-6 months (2%) and remained stable at 1 year, with no evidence of honeycombing. At 1 year, lung abnormalities due to COVID-19 pneumonia were completely resolved in 78 of 84 (93%) participants.
CONCLUSION: Residual lung abnormalities in individuals hospitalized with moderate COVID-19 pneumonia were infrequent, with no evidence of fibrosis at 1-year chest CT. © RSNA, 2022.
引用
- Bocchino, Lieto, Romano, et al. Chest CT-based Assessment of 1-year Outcomes after Moderate COVID-19 Pneumonia. Radiology. 2022. PMID: 35536134. doi:10.1148/radiol.220019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。